Yao, Zhan

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 562

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

Yao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., et al. (2015) · Cancer Cell

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 543

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 479

TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences

Lung Cancer Treatments and MutationsTGF-β signaling in diseases

Cited by 389

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., et al. (2019) · Nature Medicine

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 195

Mutant-selective degradation by BRAF-targeting PROTACs

Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications

Protein Degradation and InhibitorsMelanoma and MAPK Pathways

Cited by 152

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 94